16/06/22 -"Our target price is cut on account of a drop in both intrinsic valuations (DCF and NAV) as well as the relative valuations, which now factor in the multiple near-term headwinds (supply chain ..."
Pages
65
Language
English
Published on
16/06/22
You may also be interested by these reports :
19/11/26
Dräger’s CMD delivered more than expected: Ambition 2030 targets c.€4.5bn of sales and a 10–12% EBIT margin, above July’s “at least 10%”, backed for ...
17/11/26
Getinge delivered a mixed Q3 26, with sales marginally below consensus but adjusted EBITA well ahead. ACT drove a sharp margin step-up, even before ...
13/11/26
DiaSorin’s Q3 performance exceeded expectations, with revenue acceleration supported by all segments and improved profitability. Full-year guidance ...
13/11/26
Coloplast reported weak Q4 FY26 numbers: revenue beat consensus slightly (+1.1%), but adjusted EBIT missed sharply (-8.4%). More importantly, the new ...